Feb 27, 2019

Alkaloid marked 10% growth in consolidated export, 7% growth in consolidated net profit, investments of MKD 1.1 billion and 212 new employments in the period January - December 2018

Alkaloid AD Skopje achieved positive financial results in the period January-December 2018 - shows the unaudited standalone and unaudited consolidated Income Statement

According to the unaudited standalone Income Statement, in the period January- December the sales reached the amount of MKD 7,506,114,294 - 8% up on the same period last year. Earnings before interest, taxes, depreciation and amortization (EBITDA), which amount to MKD 1,478,890,871 marked an increase of roughly 13%, whereas the net profit amounting to MKD 848,199,257 rose by 11%.

In the period January – December the total consolidated sales reached MKD 9,783,285,973 – an increase of 8% compared to the same period last year.

Consolidated sales in the domestic market increased 4%, while the total consolidated export of the company which exceeded EUR 100 million for the first time, increased by 10%. Out of the total consolidated sales, 37% were realized in the domestic market, while the foreign markets account for 63%. The breakdown by region shows that the countries of South-East Europe account for 35% of the sales, Russia and CIS – 6%, 21% of the sales were realized in the countries from Western Europe (EU and EFTA), while the other markets account for 1% of the total consolidated sales. Noticeable rise was seen in Hungary reaching sales of MKD 128,111,848 - increased by 4 times, Poland reaching sales of MKD 72,260,692 - increased by 4 times and Ukraine with sales of MKD 192,130,438 – increased by 86% compared to the same period last year. Growth in sales was also marked in the following export markets: Czech Republic - 62%, Georgia – 51%, USA – 22%, Serbia - 21%, Kosovo - 20%, Bulgaria - 10%, Romania – 5%, etc.

The breakdown of total consolidated sales by group of products shows that the best sellers are the products from the segment Pharmaceuticals – 85%, with OTC products accounting for 22%, cardiovascular products - 17%, antibiotics - 14%, neurological products – 13% etc. The Chemistry Cosmetics Botanicals segment accounts for 15% of the total consolidated sales, or more precisely Chemistry – 3%, Cosmetics – 9% and Botanicals – 3%.

Consolidated earnings before interest, taxes, depreciation and amortization (EBITDA), which reached MKD 1,555,516,762 saw an increase of 10%, whereas the net consolidated profit amounting to MKD 862,410,928 went up by 7%.

The total investments in non-current assets for the period January – December 2018 amounted to MKD 1,081,736,913 - an increase of 26% compared to 2017.

In the period January – December 2018 Alkaloid recruited 212 new employees in the Republic of North Macedonia.